Alphadyne Asset Management LP
Position in VRTX — Vertex Pharmaceuticals Inc / Ma
CIK 1535943
NEW YORK, NY
Position in VRTX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,984,029
+$3,984,029 QoQ
Shares Held
8,922
Ownership
0.004%
of shares outstanding
% of Portfolio
0.55%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in VRTX
reported options exposure · as of Mar 31, 2026CallValue
$6,564,138
CallShares
14,700
PutValue
$10,091,804
PutShares
22,600
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Alphadyne Asset Management LP holds $5,118,929 across 5 Biotechnology names. VRTX ranks #1 (77.8% of the industry book) .
All Filings in VRTX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,564,138 | 14,700 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $10,091,804 | 22,600 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $3,984,029 | 8,922 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $906,720 | 2,000 | Put | Sole | 2026-02-17 | |
| 2025-12-31 | $906,720 | 2,000 | Call | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||